Last updated: June 8, 2023
Sponsor: Sun Yat-sen University
Overall Status: Active - Recruiting
Phase
N/A
Condition
Heavy Bleeding / Heavy Periods
Female Hormonal Deficiencies/abnormalities
Perimenopause
Treatment
prophylactic HPV vaccine(bivalent HPV、quadrivalent HPV、9-valent HPV)
Clinical Study ID
NCT05838157
2022111615154477
Ages 16-40 Female Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Previous menstrual cycles were regular and normal
- At least one vaccination of HPV vaccine
Exclusion
Exclusion Criteria:
- Pregnancy
- Breast-feeding
- Record of abnormal results of HPV test/ cervical cytology/ gynecologicalultrasonography
- Record of medications related to menstruation
- Diseases contribute to menstrual irregularities、amenorrhea such as severe anemia/coagulation disorders/ thyroid dysfunction etc.
- Participation in other clinical trials
Study Design
Total Participants: 600
Treatment Group(s): 1
Primary Treatment: prophylactic HPV vaccine(bivalent HPV、quadrivalent HPV、9-valent HPV)
Phase:
Study Start date:
May 04, 2023
Estimated Completion Date:
December 31, 2024
Study Description
Connect with a study center
Cancer Prevention Center,Sun Yat-sen University Cancer Cente
Guangzhou, Guangdong 510000
ChinaActive - Recruiting
Sun Yat-sen University Cancer Cente
Guangzhou, Guangdong 510000
ChinaSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.